Innovative immunological and target therapies for NMIBC: Recent clinical trial data shaping the future : Episode 1
Opinion
Video
Unmet Needs & Standard of Care for Intermediate-High Risk NMIBC
Gary D. Steinberg, MD, discusses the unmet needs and current standard of care for patients with intermediate and high-risk non-muscle-invasive bladder cancer (NMIBC).
Video Player is loading.
- What are some of the unmet needs in the treatment of non-muscle-invasive bladder cancer (NMIBC)?
- Patients with intermediate and high risk NMIBC
- Disease burden/effects on QoL
2. What is the current standard of care for patients with intermediate-risk or high risk NMIBC?
- Surgical resection
- Discuss shortage of BCG
Related Videos
Factors Contributing to Higher Incidence and Worse Outcomes of mHSPC in Black Men
The Incidence of Prostate Cancer and Risk of Progression in Black Men
The Biggest Challenges in Distinguishing ccRCC From Benign Renal Masses
The Evolvement of Imaging in ccRCC
Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
Comparing Trials Studying Treatment Intensification In mHSPC
Impact of Robotic Procedures and Apps on Clinic Efficiency
An Overview of the ARANOTE Trial
Abiraterone Acetate: Generic and Branded Options
A 69-Year-Old Man With Metastatic Hormone Sensitive Prostate Cancer
Related Content
